Therapeutic angiogenesis: Protein and gene therapy delivery strategies

European Journal of Preventive Cardiology

Volumn 6, Issue 1, 1999, Pages 29-40

  Rosengart, Todd K ^a   Patel, Shailen R ^a,b   Crystal, Ronald G ^b  

^a Department of Cardiothoracic Surgery ^*

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

angiogenesis; gene therapy; vascular endothelial growth factor

Indexed keywords

FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL OCCLUSION; BYPASS SURGERY; GENE TARGETING; GENE THERAPY; PRIORITY JOURNAL; PROTEIN INDUCTION; TREATMENT CONTRAINDICATION; VASCULARIZATION;

ARTERIOSCLEROSIS; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTORS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 84992791224     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/204748739900600106     Document Type: Review

References (169)

1. Beck L Jr., D'Amore PA. Vascular development: cellular and molecular recognition. FASEB J 1997; 11: 365–373.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1995; 1: 27–31.
3. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931–10934.
4. Klagsbrun M, Folkman J. Angiogenesis. In: Sporn MB, Robert AB (editors): Peptide growth factors and their receptors II. Bering, Heidelberg, New York: Springer; 1990. pp. 549–574.
5. Montesano R. 1992 Mack Forster Award Lecture. Regulation of angiogenesis in vitro [review]. Eur J Clin Invest 1992; 22: 504–515.
6. Risau W. Angiogenic growth factors. Prog Growth Factor Res. 1990; 2: 71–79.
7. Weinstat-Saslow D, Steeg PS. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 1994; 8: 401–407.
8. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327–336.
9. Folkman J, Haudenschild C. Angiogenesis in vitro. Nature 1980; 288: 551–556.
10. Longland CJ. The collateral circulation of the limb. Ann R Coll Surg Engl 1953; 13: 161–181.
11. Piek JJ, Becker AE. Collateral blood supply to the myocardium at risk in human myocardial infarction: a quantitative post-mortem assessment. J Am Coll Cardiol 1988; 11: 1290–1296.
12. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217–239.
13. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Ann Rev Biochem 1989; 58: 575–606.
14. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol Rev 1992; 13: 18–32.
15. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 1806–1814.
16. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 1994; 28: 1176–1179.
17. Rosengart T, Duenas M, Winkles J, Krieger K, Isom OW. Ischemia is associated with increased expression of the angiogenic protein acidic fibroblast growth factor: implications for ‘biologic’ revascularization. Surg Forum 1994; 45: 392–395.
18. Shweiki D, Itin A, Softer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843–845.
19. Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 1994; 267: H1948–H1954.
20. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994; 90: 649–652.
21. Chleboun JO, Martins RN, Mitchell CA, Chrilla TV. Basic FGF enhances the development of the collateral circulation after acute arterial occlusion. Biochem Biophys Res Commun 1992; 185: 510–516.
22. Sellke F, Li J, Stamler A, Lopez J, Thomas K, Simons M. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery 1996; 120: 182–188.
23. Lazarous DF, Shou M, Scheinowitz H, Hodge E, Thirumurti V, Kitsiou AN, et al Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996; 94: 1074–1082.
24. Horrigan M, MacIsaac A, Nicolini F, Vince D, Lee P, Ellis S, Topol E. Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model. Circulation 1996; 94: 1927–1933.
25. Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S, et al Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995; 91: 145–153.
26. Unger E, Banai S, Shou M, Lazarous D, Jaklitsch M, Scheinowitz M, et al Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994; 266: H1588–H1595.
27. Harada K, Grossman W, Friedman M, Edelman E, Prasad P, Keighley C, et al Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994; 94: 623–630.
28. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, et al Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992; 257: 1401–1403.
29. Harada K, Friedman M, Lopez JJ, Wang SY, Li J, Prasad PV, et al Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996; 270: H1791–H1802.
30. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, et al Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994; 89: 2183–2189.
31. Pu LQ, Sniderman AD, Brassard R, Lachapelle KJ, Graham AM, Lisbona R, Symes JF. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 1993; 88: 208–215.
32. Rosengart TK, Budenbender KT, Duenas M, Mack CA, Zhang Q-X, Isom OW. Therapeutic angiogenesis: a comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin. J Vasc Surg 1997; 26: 302–312.
33. Carroll SM, White FC, Roth DM, Bloor CM. Heparin accelerates coronary collateral development in a porcine model of coronary artery occlusion. Circulation 1993; 88: 198–207.
34. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, et al Therapeutic angiogenesis: a single arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J Clin Invest 1994; 63: 662–670.
35. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 1995; 21: 314–324.
36. Takeshita S, Pu LQ, Stein LA, Sniderman AD, Ferrara N, Isner JM, Symes JF. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994; 90 (suppl II): II228–II234.
37. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995; 92 (suppl II): II365–II371.
38. Sharma HS, Sassen L, Knoll R, Verdouw PD. Myocardial expression of vascular endothelial growth factor: enhanced transcription during ischemia and reperfusion [abstract]. Circulation 1992; 86 (suppl I): I1168.
39. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996; 94: 1647–1654.
40. Brogi E, Schatteman G, Wu T, Kim E, Varticovski L, Keyt B, Isner J. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 1996; 97: 469–476.
41. Li J, Brown L, Hibberd M, Grossman J, Morgan J, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996; 270: H1803–H1811.
42. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995; 270: 19761–19766.
43. Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clause M, Pinsky DJ, et al Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 1995; 92: 4606–4610.
44. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, et al Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996; 93: 8502–8507.
45. Kong HL, Song WR, Hecht D, Yayon A, Kouesdi I, Crystal RG. Inhibition of angiogenesis and tumor growth following adenovirus vector-mediated in vivo transfer of the human soluble Flt receptor gene [abstract]. Proc Am Soc Clin Oncol 1997; 16: 428a.
46. Millauer B, Longhi MP, Plate KH, Shawvre LK, Risau W, Ullrich A, Strawn LM. Dominant-negative inhibition of flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996; 56: 1615–1620.
47. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant Nature 1994; 367: 576–579.
48. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al Isolation of putative progenitor endothelial cells for angigenesis. Science 1997; 275: 964–967.
49. DeLisser HM, Newman PJ, Albeida SM. Molecular and functional aspects of PECAM-1/CD31. Immunol Today 1994; 15: 490–498.
50. Qing-Xue J, Rosengart TK. Proteolytic modification of vascular endothelial growth factor: implications for extracellular matrix regulation of angiogenesis [abstract]. Circulation 1995; 92 (suppl 8): II12.
51. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031–26037.
52. Leung D, Cachianes G, Kuang W-J, Goeddel D, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–1309.
53. Park J, Keller G-A, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Chem 1993; 4: 1317–1326.
54. Saksela O, Rifkin DB. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990; 110: 767–775.
55. Ishai-Michaeli R, Eldor A, Vlodavsky I. Heparanase activity expressed by platelets, neutrophils and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Regul 1990; 1: 833–842.
56. Basilico C, Moscatelli D. The FGF family growth factors and oncogenes. Adv Canc Res 1992; 59: 115–165.
57. Denhardt DT. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. J Biochem 1996; 318: 729–747.
58. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275–288.
59. Gospodarowicz D, Ferrar N, Schweigerer L, Neufeld G. Structural characterization and biologic functions of fibroblast growth factor. Endocrine Rev 1987; 8: 95–114.
60. Slavin J. Fibroblast growth factors: at the heart of angiogenesis. Cell Biol int 1995; 19: 431–444.
61. Houssaint E, Blanquet P, Champion-Arnoud P, Gesnel MC, Torriglia A, Courtois Y, et al Related fibroblast growth factor receptor genes exist in the human genome. Proc Natl Acad Sci USA 1990; 87: 8180–8184.
62. Johnson D, Lee P, Lu J, Williams L. Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol 1990; 10: 4728–4736.
63. Moscatelli D. Metabolism of receptor-bound and matrix-bound basic fibroblast growth by bovine capillary endothelial cells. J Cell Biol 1988; 107: 753–759.
64. Yayon A, Klagsbrun M, Esko J, Leder P, Ornitz D. Cell surface heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64: 841–848.
65. Brown KJ, Hendry IA, Parish CR. Acidic and basic fibroblast growth factor bind with differing affinity to the same heparan sulfate proteoglycan on BALB/c 3T3 cells: implications for potentiation of growth factor action by heparin. J Cell Biochem 1995; 58: 6–14.
66. Reich-Slotky R, Bonneh-Barkay D, Shaoul E, Bluma B, Svahn CM, Ron D. Differential effect of cell-associated heparan sulfates on the binding of keratinocyte growth factor (KGF) and acidic fibroblast growth factor to the KGF receptor. J Biol Chem 1994; 269: 32279–32285.
67. Brindle NPJ. Growth factors in endothelial regeneration. Cardiovasc Res 1993; 27: 1162–1172.
68. Baird A, Bohlen P. Fibroblast growth factors. In: Sporn MB, Roberts AD (editors). Peptide growth factors and their receptors. Berlin, Heidelberg, New York: Springer; 1990. pp. 369–418.
69. Mason I. Cell signalling. Do adhesion molecules signal via FGF receptors? Curr Biol 1994; 4: 1158–1161.
70. Schlessinger J, Lax I, Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell 1995; 83: 357–360.
71. Doherty P, Smith P, Walsh FS. Shared cell adhesion molecule (CAM) homology domains point to CAMs signalling via FGF receptors. Perspect Dev Neurobiol 1996; 4: 157–168.
72. Viollet C, Doherty P. CAMs and the FGF receptor: an interacting role in axomal growth. Cell Tiss Res 1997; 290: 451–455.
73. Gospodarowicz D, Abraham J, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo steliate cells. Proc Natl Acad Sci USA 1989; 86: 7311–7315.
74. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 861–858.
75. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family. Oncogene 1990; 5: 519–524.
76. Terman B, Dougher-Vermazen M, Carrion M, Dimitrov AD, Armellino D, Gospodarowicz D, et al Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992; 187: 1579–1586.
77. Ferrara N, Houck K, Jakeman L, Winer J, Leung D. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47: 211–218.
78. Tischer E, Gospodarowicz D, Mitchell R, Silva M, Schilling J, Lau K, et al Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 1989; 165: 1198–1206.
79. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, et al Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996; 93: 2576–2581.
80. Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, et al Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997; 272: 25176–25183.
81. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi B-Z. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994; 5: 89–97.
82. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes J, Abraham J. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266: 11947–11954.
83. Takeshita S, Yukio T, Thierry C, Takayuki A, Bauters C, Symes J, et al Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest 1996; 75: 487–501.
84. McNeil PL, Muthukrishan L, Warder E, D'Amore PA. Growth factors are released by mechanically wounded endothelial cells. J Cell Biol 1989; 109: 811–822.
85. Gajdusek CM, Carbon S. Injury induced release of basic fibroblast growth factor from bovine aortic endothelial cells. J Cell Physiol 1989; 139: 570–579.
86. O'Reilly MA, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315–328.
87. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705–10709.
88. Schumacher B, Percher P, von Specht BU, Stegman T. Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation 1998; 97: 645–650.
89. Hariawala M, Horowitz J, Esakof D, Sherrif D, Walter D, Keyt B, et al VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996; 63: 77–82.
90. Banai S, Jaklitsch MT, Casscells W, Shou K, Shrivastav S, Correa R, et al Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ Res 1991; 69: 76–85.
91. Sellke FW, Wang SY, Friedman M, Harada K, Edelman ER, Grossman W, et al Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation. Am J Physiol 1994; 267: H1303–1311.
92. Magovern CJ, Mack CA, Zhang J, Rosengart TK, Isom OW, Crystal RG. Regional angiogenesis induced in non-ischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther 1997; 8: 215–227.
93. Yang RH, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B, et al Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996; 27: 838–844.
94. Baumgartner I, Magner M, Pieczek AM, Isner JM. Clinical evidence that vascular endothelial growth factor enhances vascular permeability [abstract]. Circulation 1997; 96: I491.
95. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, et al Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370–374.
96. Rakhmilevich AL, Janssen K, Turner J, Culp J, Yanf NS. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther 1997; 8: 1303–1311.
97. Pinnaduwage P, Schmitt L, Huang L. Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells. Biochem Biophys Acta 1989; 985: 33–37.
98. Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 1995; 34: 12877–12883.
99. Magovern CJ, Mack CA, Zhang J, Hahn RT, Ko W, Isom OW, et al Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector. Ann Thorac Surg 1996; 62: 425–434.
100. Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, et al Biological bypass utilizing adenovirus-mediated gene transfer of the cDNA for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thor Cardiovasc Surg 1998; 115: 167–177.
101. Mack CA, Magovern CJ, Budenbender KT, Patel SR, Schwarz EA, Zanzonico P, et al Salvage angiogenesis induced by adenoviral-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 1998; 27: 699–709.
102. Jejunkar SS, Welling TH, Zelenock JA, Gordon D, Burkel WE, Carlson BM, et al Induction of angiogenesis by lidocaine and basic fibroblast growth factor: a novel model for in vivo retroviral-mediated gene therapy. J Surg Res 1997; 67: 137–146.
103. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, et al Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nature Med 1996; 2: 534–539.
104. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407–4411.
105. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004–2015.
106. Yang Y, Joos KU, Su Q, Ertl HCJ, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996; 3: 137–144.
107. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404–410.
108. Human gene marker/therapy clinical protocols. Hum Gene Ther 1996; 7: 567–586.
109. Isner JM. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther 1996; 7: 959–988.
110. Lin H, Parmacek MS, Morle G, Bolling S, Leiden JM. Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation 1990; 82: 2217–2221.
111. Dai Y, Roman M, Naviaux RK, Verma IM. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 1992; 89: 10892–10895.
112. St Louis D, Verma IM. An alternative approach to somatic cell gene therapy. Proc Natl Acad Sci USA 1988; 85: 3150–3154.
113. Palmer TD, Rosman GJ, Osborne WR, Miller AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 1991; 88: 1330–1334.
114. Safi J Jr., Gloe TR, Riccioni T, Kovesdi I, Capogrossi MC. Gene therapy with angiogenic factors: a new potential approach to the treatment of ischemic disease. J Mol Cell Cardiol 1997; 29: 2311–2325.
115. Stewart MJ, Plautz GE, Del Buono L, Yang ZY, Xu L, Gao X, et al Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther 1992; 3: 267–275.
116. Nabel EG, Pompili VJ, Plautz GE, Nabel GJ. Gene transfer and vascular disease. Cardiovasc Res 1994; 28: 445–455.
117. Horwitz MS. Adenoviridae and their replication. Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, et al(editors): Virology. New York: Raven; 1990. pp. 1679–1740.
118. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, et al Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet 1994; 8: 42–51.
119. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, et al In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to airway epithelium. Cell 1992; 68: 143–155.
120. Zabner J, Petersen DM, Puga AP, Graham SM, Couture LA, Keyes D, et al Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nature Genet 1994; 6: 75–83.
121. Crystal RG, Rosengart TK, Isom O Wayne, Devereux RB, Sanborn TA, Zanzonico P, et al Phase I study of direct administration of a replication deficient adenovirus vector (AdGVVEGF121.10) containing the VEGF121 cDNA to the ischemic myocardium of individuals with life threatening diffuse coronary artery disease. RAC Report #9711–221. Office of Recombinant DNA activities, National Institutes of Health, Suite 323, 6006 Executive Boulevard, MSC 7052, Bethesda, MD 20892-7052, USA.
122. Kotin RM, Sininscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, et al Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87: 2211–2215.
123. Berns KI, Kotin RM, Labow MA. Regulation of adeno-associated virus DNA replication. Biochim Biophys Acta 1988; 951: 425–429.
124. Lebkowski JS, McNally MM, Okarma TB, Lerch LB. Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types. Mol Cell Biol 1988; 8: 3988–3996.
125. Samulski RJ, Chang LS, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol 1987; 61 3096–3101.
126. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63: 3822–3828.
127. Kaplitt MG, Xiao X, Samulski RJ, Li J, Ojamaa K, Klein IL, et al Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann Thorac Surg 1996; 62: 1669–1676.
128. Cone RD, Mulligan RC. High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host gene. Proc Natl Acad Sci USA 1984; 81: 6349–6353.
129. Milano CA, Allen AF, Rockman HA, Dolber PC, McMinn TR, Chien KR, et al Enhanced myocardial function in transgenic mice over-expressing the beta-2 adrenergic receptor. Science 1994; 264: 582–586.
130. Rothmann T, Katus HA, Hartong R, Perricaudet M, Franz WM. Heart-muscle specific gene expression using replication deficient recombinant adenovirus. Gene Ther 1996; 3: 919–926.
131. Hirt RP, Poulain-Godefroy O, Billotte J, Kraehenbuhl JP, Fasel N. Highly inducible synthesis of heterologous proteins in epithelial cells carrying a glucocorticoid-responsive vector. Gene 1992; 111: 199–206.
132. Adesanya MR, Redman RS, Baum BJ, O'Connell BC. Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands. Hum Gene Ther 1996; 7: 1085–1093.
133. Joos K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996; 7: 1555–1566.
134. Mastrangei A, Harvey BG, Yao J, Wolf G, Kovesdi I, Crystal RG, Falck-Pedersen E. ‘Sero-switch’ adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat administration by changing the adenovirus serotype. Hum Gene Ther 1996; 7: 79–87.
135. Mack CA, Song W-R, Carpenter H, Wickham T, Kovesdi I, Harvey B-G, et al Circumvention of anti-adenovirus neutralizing immunity by administration of an alternate serotype. Hum Gene Ther 1997; 8: 99–109.
136. Folkman J, Klagsburn M. Angiogenic factors. Science 1987; 235: 442–447.
137. Thomas KA. Fibroblast growth factors. FASEB J 1987; 1: 434–440.
138. Rifkin DB, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989; 109: 1–6.
139. Gospodarowicz D. Fibroblast growth factor and its involvement in developmental processes. Curr Topics Dev Biol 1990; 24: 57–93.
140. Bicknell R, Vallee BL. Angiotensin activates endothelial cell phospholipase C. Proc Natl Acad Sci USA 1988; 85: 5961–5965.
141. Bicknell R, Vallee BL. Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2. Proc Natl Acad Sci USA 1989; 86: 1573–1577.
142. Shapiro R, Riordan JF, Vallee BL. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry 1986; 25: 3527–3532.
143. St Clair DK, Rybak SM, Riordan JF, Vallee BL. Angiogenin abolishes cell-free protein synthesis by specific ribonucleolytic inactivation of ribosomes. Proc Natl Acad Sci USA 1987; 84: 8330–8340.
144. Hu G, Riordan JF, Vallee BL. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci USA 1994; 91: 12096–12100.
145. Hu GF, Riordan JF. Angiogenin enhances actin acceleration of plasminogen activation. Biochem Biophys Res Commun 1993; 197: 682–687.
146. Badet J, Soncin F, Barritault D. Angiogenin and endothelial cells. EXS 1992; 61: 235–238.
147. Heldin CH, Usuki K, Miyazono K. Platelet-derived endothelial cell growth factor. J Cell Biochem 1991; 47: 208–210.
148. Miyazono K, Usuki K, Heldin CH. Platelet-derived endothelial cell growth factor. Prog Growth Factor Res 1991; 3: 207–217.
149. Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232: 1250–1253.
150. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83: 4167–4177.
151. Madri JA, Pratt BM, Tucker AM. Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix. J Cell Biol 1988; 106: 1375–1384.
152. Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 1987; 105: 957–963.
153. Yang EY, Moses HL. Transforming growth factor beta 1-induced changes in cell migration, proliferation and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990; 111: 731–741.
154. Okamura K, Sato Y, Matsuda T, Hamanaka R, Ono M, Kohno K, Kuwano M. Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in tumor necrosis factor-treated human microvascular endothelial cells. J Biol Chem 1991; 266: 19162–19165.
155. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same coin. Nature 1986; 320: 584–588.
156. Sato N, Fukuda K, Nariuchi H, Sagara N. Tumor necrosis factor inhibiting angiogenesis in vitro. J Natl Cancer Inst 1987; 79: 1383–1391.
157. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-alpha. Nature 1987; 329: 630–632.
158. Frater-Schroder M, Risau W, Hallman R, Gautschi P, Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84: 5277–5281.
159. Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol 1992; 140: 539–544.
160. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181: 902–906.
161. Takeshita S, Rossow ST, Kearney M, Zheng LP, Bauters C, Bunting S, et al Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 1995; 147: 1649–1660.
162. Rosen EM, Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, et al Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo. Symp Soc Exp Biol 1993; 43: 227–234.
163. Camussi G, Montrucchio G, Lupia E, Soldi R, Comoglio PM, Bussolini F. Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages. J Immunol 1997; 158: 1302–1309.
164. Morimoto A, Tada K, Nakayama Y, Kohno K, Naito S, Ono M, Kuwano M. Cooperative roles of hepatocyte growth factor and plasminogen activator in tubular morphogenesis by human microvascular endothelial cells. Jpn J Cancer Res 1994; 85: 53–62.
165. Mizuno K, Nakamura T. Molecular characteristics of HGF and the gene, and its biochemical aspects. EXS 1993; 65: 1–29.
166. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59: 115–165.
167. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986; 83: 7297–7301.
168. Finch PW, Rubin JS, Miki T, Ron D, Aaronson SA. Human KGF is FGF related with properties of a paracrine effector of epithelial cell growth. Science 1989; 245: 752–755.
169. Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H, Matsumoto K. Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci USA 1992; 89: 8928–8932.